Triso

Company Overview

Snapshot

Founded in November 2016 by David Abargel and Michael Lyons, Triso operates with 11–50 employees. The company has secured funding across three rounds, including a grant from the Israel Innovation Authority in July 2020.

Business overview

Triso develops a platform for the automatic analysis and evaluation of anatomic images, offering a wide range of functionalities for various medical disciplines. Its patented software accurately determines and defines the boundaries of anatomic features from ultrasounds, CTs, and X-rays. The company's product portfolio includes LV-Tricardio, a fully automated echocardiogram imaging platform, and TriAngeo, which automatically traces arterial networks across angiogram images. Triso primarily serves the digital healthcare market, specifically digital medical diagnostics, and targets healthcare providers in the United States.

Company Intelligence Q&A

What is Triso's primary focus?

Triso focuses on developing a platform for the automatic analysis and evaluation of anatomic images, servicing various medical disciplines with its patented imaging technology.

When was Triso founded?

Triso was founded in November 2016 by David Abargel and Michael Lyons.

What are Triso's key products?

Triso's key products include LV-Tricardio, a fully automated echocardiogram imaging platform, and TriAngeo, which automatically traces arterial networks across angiogram images.

Which markets does Triso serve?

Triso primarily serves the digital healthcare market, specifically digital medical diagnostics, and targets healthcare providers in the United States.

Has Triso received any grants?

Yes, Triso secured a grant from the Israel Innovation Authority in July 2020 and another grant from KamaTech in March 2017.